Landsteiner Genmed Obtains 2,055M € of Non-Dilutive Funding from Next Generation EU Funds to Develop New Anticancer Immunomodulatory Agents

27/01/2023 | Landsteiner Genmed

Landsteiner Genmed has announced that it has obtained 2,055M € of non-dilutive funding from Next Generation EU Funds to study the anticancer effects of new molecules with immunomodulatory properties.

Landsteiner Genmed and Vall d’Hebron Institute of Research Communicate Pioneering Preclinical Efficacy Data on the New Compound NPO-2270 in Heart Failure Models

30/04/2022 | Landsteiner Genmed

NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in two experimental models of heart failure.

For further information about our studies

Ask us

Home - News & events

Categories

Latest news and events

For further information about our studies